Frontlight ResearchEarly access
Migraine trials in Italy
11 of 31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Active, not recruitingA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- Where
- Cagliari, Florence, Genoa, Milan, Pavia, Rome
- Age
- 12 years to 17 years
- People
- 285 worldwide
- Run by
- H. Lundbeck A/S
See details and how to joinNCT04965675 · EU 2024-510656-13-00 - Phase 3Taking peopleEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Where
- Avellino, Bari, Brescia, Florence, Genoa, Latina, Milan, Padova, Pavia, Pisa, Rome
- Age
- 6 years to 17 years
- People
- 640 worldwide
- Run by
- Pfizer
See details and how to joinNCT05156398 · EU 2024-512382-13-00 - Phase 3Taking peopleA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- Where
- Cagliari, Florence, Genoa, Milan, Pavia, Pisa, Rome
- Age
- 6 years to 17 years
- People
- 600 worldwide
- Run by
- H. Lundbeck A/S
See details and how to joinNCT05164172 · EU 2022-502917-27-00 - Phase 3Taking peopleA Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- Where
- Cagliari, Genoa, Milan, Pavia, Pisa, Rome
- Age
- 6 years to 17 years
- People
- 315 worldwide
- Run by
- H. Lundbeck A/S
See details and how to joinNCT05897320 · EU 2022-502538-14-00 - Phase 3Taking peopleA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Where
- Milan, Rome
- Age
- 12 years to 17 years
- People
- 420 worldwide
- Run by
- AbbVie
See details and how to joinNCT06810505 · EU 2024-513836-28-00 - Phase 3Taking peopleA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- Where
- Milan, Palermo, Rome
- Age
- 6 years to 17 years
- People
- 450 worldwide
- Run by
- AbbVie
See details and how to joinNCT05711394 · EU 2022-501100-94-00 - Phase 3Active, not recruitingA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- Where
- Bologna, Florence, L'aquila, Milan, Pavia, Rome
- Age
- 18 years to 45 years
- People
- 723 worldwide
- Run by
- Pfizer
See details and how to joinNCT06641466 · EU 2024-517121-10-00 - No phaseTaking peopleEvaluation of the Performance of the Doraldo-Castelletti Scale in Supporting the Neurologist's Decision to Refer Migraine Patients to Physiotherapy
- Where
- Milan
- Age
- 18 years to 70 years
- People
- 439
- Run by
- Istituto Auxologico Italiano
See details and how to joinNCT07626307 - No phaseTaking peopleStudy on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy
- Where
- Florence
- Age
- 18 years to 65 years
- People
- 30
- Run by
- University of Florence
See details and how to joinNCT03404336 - Phase 4Taking peopleExploring Eptinezumab: Unveiling Peripheral and Central Mechanisms of Action and Searching for Biomarkers of Patient Response (EUPHORIA Study)
- Where
- Milan
- Age
- 18 years and over
- People
- 60
- Run by
- Ospedale San Raffaele S.r.l.
See details and how to join2024-519337-35-00 - Phase 3Taking peopleLong-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
- Where
- Milan, Palermo, Rome
- Age
- 6 years to 17 years
- People
- 650 worldwide
- Run by
- AbbVie
See details and how to joinNCT05707949 · EU 2022-501099-24-00